Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

PURPOSE: To determine the clinical and biologic effects of bevacizumab, an anti–vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Adults with organ-confined HCC, Eastern Cooperative Oncology Group performance status o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Siegel, Abby B., Cohen, Emil I., Ocean, Allyson, Lehrer, Deborah, Goldenberg, Alec, Knox, Jennifer J., Chen, Helen, Clark-Garvey, Sean, Weinberg, Alan, Mandeli, John, Christos, Paul, Mazumdar, Madhu, Popa, Elizabeta, Brown, Robert S., Rafii, Shahin, Schwartz, Jonathan D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3635806/
https://ncbi.nlm.nih.gov/pubmed/18565886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.15.9947
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados